Table 4. Performance of hrHPV testing for the detection of CIN2/3 six months after cryotherapy.
Post- treatment | TP | FP | FN | TN | Sensitivity | Specificity | PPV | NPV |
hrHPV | 17 | 39 | 1 | 22 | 0.94 (0.73–1.00) | 0.36 (0.24–0.49) | 0.30 (.19–0.44) | 0.96 (0.78–1.00) |
HPV16 | 7 | 6 | 11 | 55 | 0.39 (0.17–0.64) | 0.90 (0.80–0.96) | 0.54 (0.25–0.81) | 0.83 (0.72–0.91) |
HPV18 | 4 | 8 | 14 | 53 | 0.22 (0.06–0.48) | 0.87 (0.76–0.94) | 0.33 (0.10–0.65) | 0.79 (0.67–0.88) |
HPV16/18 | 11 | 14 | 7 | 47 | 0.61 (0.36–0.83) | 0.77 (0.65–0.87) | 0.44 (0.24–0.65) | 0.87 (0.75–0.95) |
Persistent hrHPV1 | 17 | 32 | 1 | 29 | 0.94 (0.73–1.00) | 0.48 (0.35–0.61) | 0.35 (0.22–0.50) | 0.97 (0.83–1.00) |
Kenya, 79 HIV-positive women.
At least 1 same hrHPV type present before and 6 months after cryotherapy.
TP, true positive, FP, false positive, FN, false negative, TN, true negative, PPV, positive predictive value, NPV, negative predictive value, hrHPV, high-risk human papillomavirus.